We’re testing a new AI assistant to help patients, caregivers, and researchers find information faster. Click the FCF Assistant button in the lower right corner to try it.
Kurt Losert 
FCF is pleased to announce that it has awarded a grant to Aleksander Skardal, PhD, of Ohio State University to develop new models of fibrolamellar carcinoma (FLC). A major challenge to researching FLC is the scarcity of lab models that accurately mimic how this cancer behaves in the human body. To address this, the team …
The FCF is pleased to announce the funding of a study led by Dr. Sean Ronnekleiv-Kelly of the University of Wisconsin-Madison. This research will explore a key protein, SLC16A14, that is involved in the growth and survival of fibrolamellar cancer (FLC) cells using a new mouse model that the team has developed. Evidence suggests that …
A new clinical trial for fibrolamellar patients is now enrolling patients! This phase 1/2 study, Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma, will test the safety, side effects and best dose of DT2216 in combination with the chemotherapy agent, irinotecan. …
From June 9 – 11, FCF is hosting its sixth Fibrolamellar Scientific Summit. The goal of this meeting is to bring together the fibrolamellar research community to share research knowledge and to collaborate in the search for a cure. To encourage the sharing of unpublished information, the scientific discussions in the main session will be …
Congratulations to Marina Baretti, MD of Johns Hopkins University! On May 30, she was recognized with a Career Development Award (CDA) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This highly prestigious award provides three years of research funding to clinical investigators to establish an independent clinical cancer research program. These awards …
The Fibrolamellar Cancer Foundation is pleased to announce that it has awarded an exploratory research grant to Dr. Hugo Jimenez at Wayne State University to investigate the effectiveness of using low energy electromagnetic fields to treat fibrolamellar carcinoma (FLC). In this study, Dr. Jimenez and his team will conduct initial feasibility testing with a device …
FCF is pleased to announce that it is funding an extension of a clinical trial at the Johns Hopkins Kimmel Cancer Center in Baltimore, MD that tests the ability of a FLC-specific vaccine to produce an immune response against the disease. With this new funding, the trial will be able to enroll 16 additional patients. …
In the video below, Dr. Juliane Walz discusses a new clinical trial that is now open to patient enrollment at The University Hospital Tübingen in Tübingen, Germany. This FusionVAC22_02 clinical trial is designed to test the safety and efficacy of a peptide vaccine to delay or prevent the recurrence of fibrolamellar carcinoma (FLC). The peptide …
Cancers grow through uncontrolled cell proliferation. Repeated rounds of division of single cells to yield “daughter” cells cause tumors to expand exponentially. Cancer therapy aims not only to slow down or prevent cell division, but also to cause the malignant cells to die. Efficient killing is crucial because even a tumor that is barely detectable …